Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas

Journal of Gastroenterology

Volumn 42, Issue 5, 2007, Pages 389-394

  Itoi, Takao ^a   Sofuni, Atsushi ^a   Fukushima, Noriyoshi ^a   Itokawa, Fumihide ^a   Tsuchiya, Takayoshi ^a   Kurihara, Toshio ^a   Moriyasu, Fuminori ^a   Tsuchida, Akihiko ^a   Kasuya, Kazuhiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

EUS FNA; Pancreatic cancer; Predictive marker; RRM2

Indexed keywords

GEMCITABINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M2; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PROTEIN SUBUNIT; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2;

ADULT; AGED; ALOPECIA; ARTICLE; ASPIRATION BIOPSY; ASTHENIA; BLEEDING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; INFECTION; INOPERABLE CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS BIOPSY; PANCREAS CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; THROMBOCYTOPENIA; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PANCREAS TUMOR; PATHOLOGY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY, FINE-NEEDLE; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN SUBUNITS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 34447503264     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-007-2017-0     Document Type: Article

References (24)

1. The Editorial Board of the Cancer Statistics in Japan 2001 Cancer Statistics in Japan Foundation for Promotion of Cancer Research Tokyo
2. RT Greenlee MB Hill-Harmon TM Thun 2001 Cancer statistics 2001 CA Cancer J Clin 51 15-36 11577478 1:STN:280:DC%2BD3MrjtFGisg%3D%3D
3. AM Storniolo NH Enas CA Brown M Voi ML Rothenberg R Schilsky 1999 An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma Cancer 85 1261-8 10189130 10.1002/ (SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T 1:CAS:528:DyaK1MXitVequ70%3D
4. YG Goan B Zhou E Hu S Mi Y Yen 1999 Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line Cancer Res 59 4204-7 10485455 1:CAS:528:DyaK1MXlvVSnu7o%3D
5. LM Nutter Y Cheng 1989 Nature and properties of mammalian ribonucleotide diphosphate reductase JG Cory AH Cory Inhibitors of ribonucleotide diphosphate reductase activity Pergamon Press New York 37-54
6. S Eriksson DW Martin Jr 1981 Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2 J Bio Chem 256 9436-40 1:CAS:528:DyaL3MXls1KktL8%3D
7. MS Duxbury H Ito MJ Zinner SW Ashley EE Whang 2003 RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine Oncogene 8 1-10
8. MJ Wiersema P Vilmann M Giovannini KJ Chang LM Wiersema 1997 Endosonography-guided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment Gastroenterology 112 1087-95 9097990 1:STN:280:ByiB2M3kt1U%3D
9. KJ Chang PM Nguyen RA Erickson TE Durban KD Katz 1997 The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma Gastrointest Endosc 45 387-93 9165320 10.1016/S0016-5107(97)70149-4 1:STN:280:ByiA3cfgvFA%3D
10. M Tada Y Komatsu T Kawabe N Sasahira H Isayama N Toda 2002 Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: Clinical utility for diagnosis of pancreatic tumor Am J Gastroenterol 97 2263-70 12358243 10.1111/j.1572-0241.2002.05980.x 1:CAS:528:DC%2BD38XotV2lu7k%3D
11. T Itoi K Takei A Sofuni F Itokawa T Tsuchiya T Kurihara 2005 Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses Oncol Rep 13 229-34 15643503 1:CAS:528:DC%2BD2MXhsVGrtb8%3D
12. Exocrine pancreas. In: American Joint Committee on Cancer, editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 157-64
13. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano 1977 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 2403-13
14. M Hidalgo D Castellano L Paz-Ares C Gravalos M Diaz-Puente R Hitt 1999 Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer J Clin Oncol 17 585-92 10080603 1:CAS:528:DyaK1MXht1Wmu70%3D
15. W Scheithauer GV Kornek M Raderer M Hejna J Valencak J Miholic 1999 Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma Br J Cancer 80 1797-802 10468299 10.1038/sj.bjc.6690600 1:CAS:528:DyaK1MXlvFGntbc%3D
16. V Heinemann H Wilke HG Mergenthaler M Clemens H Konig HJ Illiger 2000 Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Ann Oncol 11 1399-403 11142479 10.1023/A:1026595525977 1:STN:280:DC%2BD3M7lt12rtw%3D%3D
17. CM Rocha Lima MR Green R Rotche WH Miller Jr GM Jeffrey LA Cisar 2004 Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776-83 15365074 10.1200/JCO.2004.12.082 1:CAS:528:DC%2BD2cXhtVCitb%2FO
18. E van Cutsem H Van de Velde P Karasek H Oettle WL Vervenne A Szawlowski 2004 Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 1430-8 15084616 10.1200/JCO.2004.10.112 1:CAS:528:DC%2BD2cXpt1yjur0%3D
19. G Bepler S Sharma A Cantor A Gautam E Haura G Simon 2004 RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer J Clin Oncol 22 1878-85 15143080 10.1200/JCO.2004.12.002 1:CAS:528:DC%2BD2cXptlCksr0%3D
20. R Rosell KD Danenberg V Alberola G Bepler JJ Sanchez C Camps 2004 Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 10 1318-25 14977831 10.1158/ 1078-0432.CCR-03-0156 1:CAS:528:DC%2BD2cXhsVCqu7o%3D
21. R Rosell G Scagliotti KD Danenberg RV Lord G Bepler S Novello 2003 Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 3548-53 12789263 10.1038/sj.onc.1206419 1:CAS:528:DC%2BD3sXktlSjtrw%3D
22. RA Finch M Liu SP Grill WC Rose R Loomis KM Vasquez 2000 Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity Biochem Pharmacol 59 983-91 10692563 10.1016/ S0006-2952(99)00419-0 1:CAS:528:DC%2BD3cXht1Ohu7s%3D
23. S Wadler D Makower C Clairmont P Lambert K Fehn M Sznol 2004 Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion J Clin Oncol 22 1553-63 15117978 10.1200/JCO.2004.07.158 1:CAS:528:DC%2BD2cXpsVWmur4%3D
24. Y Yen K Margolin J Doroshow M Fishman B Johnson C Clairmont 2004 A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer Cancer Chemother Pharmacol 54 331-42 15148626 10.1007/s00280-004-0821-2 1:CAS:528:DC%2BD2cXntV2htrs%3D